{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T21:07:24Z","timestamp":1789679244100,"version":"4.0.1"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T00:00:00Z","timestamp":1729555200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Union\u2019s Horizon 2020"},{"name":"Marie Sk\u0142odowska-Curie","award":["861323"],"award-info":[{"award-number":["861323"]}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["2022-00657"],"award-info":[{"award-number":["2022-00657"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,3]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n The emergence of \u03b2-lactamase-producing bacteria has led to the use of \u03b2-lactam (BL) antibiotic and \u03b2-lactamase inhibitor (BLI) drug combinations. Despite therapeutic drug monitoring (TDM) being endorsed for BLs, the impact of TDM on BLIs remains unclear.<\/jats:p>\n <\/jats:sec>\n \n Objectives<\/jats:title>\n Evaluate whether BLIs are available in effective exposures at the site of infection and assess if TDM of BLIs could be of interest.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Population pharmacokinetic models for 9 BL and BLI compounds were used to simulate drug concentrations at infection sites following EMA-approved dose regimens, considering plasma protein binding and tissue penetration. Predicted target site concentrations were used for probability of target attainment (PTA) analysis.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Using EUCAST targets, satisfactory (\u226590%) PTA was observed for BLs in patients with typical renal clearance (CrCL of 80\u2005mL\/min) across various sites of infection. However, results varied for BLIs. Avibactam achieved satisfactory PTA only in plasma, with reduced PTAs in abdomen (78%), lung (73%) and prostate (23%). Similarly, tazobactam resulted in unsatisfactory PTAs in intra-abdominal infections (79%), urinary tract infections (64%) and prostatitis (34%). Imipenem-relebactam and meropenem-vaborbactam achieved overall satisfactory PTAs, except in prostatitis and high-MIC infections for the latter combination.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n This study highlights the risk of solely relying on TDM of BLs, as this can indicate acceptable exposures of the BL while the BLI concentration, and consequently the combination, can result in suboptimal performance in terms of bacterial killing. Thus, dose adjustments also based on plasma concentration measurements of BLIs, in particular for avibactam and tazobactam, can be valuable in clinical practice to obtain effective exposures at the target site.<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/jac\/dkae375","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T16:28:01Z","timestamp":1729614481000},"page":"79-86","source":"Crossref","is-referenced-by-count":11,"title":["Therapeutic drug monitoring (TDM) of \u03b2-lactam\/\u03b2-lactamase inhibitor (BL\/BLI) drug combinations: insights from a pharmacometric simulation study"],"prefix":"10.1093","volume":"80","author":[{"given":"Amaury","family":"O\u2019Jeanson","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Uppsala University , Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0725-214X","authenticated-orcid":false,"given":"Elisabet I","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Uppsala University , Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2979-679X","authenticated-orcid":false,"given":"Lena E","family":"Friberg","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Uppsala University , Uppsala ,","place":["Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,10,22]]},"reference":[{"key":"2025010309474114400_dkae375-B1","doi-asserted-by":"publisher","first-page":"e00115-20","DOI":"10.1128\/CMR.00115-20","article-title":"New \u03b2-lactam-\u03b2-lactamase inhibitor combinations","volume":"34","author":"Yahav","year":"2020","journal-title":"Clin Microbiol Rev"},{"key":"2025010309474114400_dkae375-B2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/2110-5820-2-35","article-title":"Does beta-lactam pharmacokinetic variability in critically Ill patients justify therapeutic drug monitoring? A systematic review","volume":"2","author":"Sime","year":"2012","journal-title":"Ann Intensive Care"},{"key":"2025010309474114400_dkae375-B3","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1093\/cid\/ciu027","article-title":"DALI: defining antibiotic levels in intensive care unit patients: are current \u03b2-lactam antibiotic doses sufficient for critically Ill patients?","volume":"58","author":"Roberts","year":"2014","journal-title":"Clin Infect Dis"},{"key":"2025010309474114400_dkae375-B4","doi-asserted-by":"publisher","first-page":"R84","DOI":"10.1186\/cc12705","article-title":"Meropenem and piperacillin\/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic\/pharmacodynamic target attainment when extended infusions are used?","volume":"17","author":"Carlier","year":"2013","journal-title":"Crit Care"},{"key":"2025010309474114400_dkae375-B5","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.burns.2015.01.001","article-title":"Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients","volume":"41","author":"Fournier","year":"2015","journal-title":"Burns"},{"key":"2025010309474114400_dkae375-B6","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s13054-017-1829-4","article-title":"Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study","volume":"21","author":"Ehmann","year":"2017","journal-title":"Crit Care"},{"key":"2025010309474114400_dkae375-B7","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.ijantimicag.2010.01.022","article-title":"Therapeutic drug monitoring of beta-lactams for critically ill patients: unwarranted or essential?","volume":"35","author":"Roberts","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"2025010309474114400_dkae375-B8","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1097\/CCM.0000000000002817","article-title":"\u03b2-lactam therapeutic drug management in the PICU","volume":"46","author":"Cies","year":"2018","journal-title":"Crit Care Med"},{"key":"2025010309474114400_dkae375-B9","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1183\/09031936.00149508","article-title":"Feedback dose alteration significantly affects probability of pathogen eradication in nosocomial pneumonia","volume":"34","author":"Scaglione","year":"2009","journal-title":"Eur Respir J"},{"key":"2025010309474114400_dkae375-B10","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1002\/phar.2505","article-title":"A guide to therapeutic drug monitoring of \u03b2-lactam antibiotics","volume":"41","author":"Fratoni","year":"2021","journal-title":"Pharmacotherapy"},{"key":"2025010309474114400_dkae375-B11","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","article-title":"Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021","volume":"47","author":"Evans","year":"2021","journal-title":"Intensive Care Med"},{"key":"2025010309474114400_dkae375-B12","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1093\/jac\/dkad223","article-title":"The clinical application of beta-lactam antibiotic therapeutic drug monitoring in the critical care setting","volume":"78","author":"Pai Mangalore","year":"2023","journal-title":"J Antimicrob Chemother"},{"key":"2025010309474114400_dkae375-B13","author":"European Medicines Agency"},{"key":"2025010309474114400_dkae375-B14","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1093\/jac\/49.1.121","article-title":"Pharmacokinetics of ceftazidime in serum and peritoneal exudate during continuous versus intermittent administration to patients with severe intra-abdominal infections","volume":"49","author":"Buijk","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"2025010309474114400_dkae375-B15","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1093\/jac\/15.1.119","article-title":"Penetration of ceftazidime into the human prostate gland following intravenous injection","volume":"15","author":"Abbas","year":"1985","journal-title":"J Antimicrob Chemother"},{"key":"2025010309474114400_dkae375-B16","author":"European Medicines Agency"},{"key":"2025010309474114400_dkae375-B17","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s40121-022-00720-x","article-title":"Ceftolozane-tazobactam pharmacokinetics in the abdominal tissue of patients undergoing lower gastrointestinal surgery: dosing considerations based on site-specific pharmacodynamic target attainment","volume":"12","author":"Yoshimura","year":"2023","journal-title":"Infect Dis Ther"},{"key":"2025010309474114400_dkae375-B18","author":"European Medicines Agency"},{"key":"2025010309474114400_dkae375-B19","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1159\/000118665","article-title":"Pharmacokinetics and pharmacodynamic assessment of imipenem in the intraperitoneal fluid of abdominal surgery patients","volume":"54","author":"Ikawa","year":"2008","journal-title":"Chemotherapy"},{"key":"2025010309474114400_dkae375-B20","author":"European Medicines Agency"},{"key":"2025010309474114400_dkae375-B21","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1179\/joc.2010.22.2.98","article-title":"Peritoneal pharmacokinetics and pharmacodynamic target attainment of meropenem in patients undergoing abdominal surgery","volume":"22","author":"Soga","year":"2010","journal-title":"J Chemother"},{"key":"2025010309474114400_dkae375-B22","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.ijantimicag.2012.11.001","article-title":"Prostatic penetration of meropenem in humans, and dosage considerations for prostatitis based on a site-specific pharmacokinetic\/pharmacodynamic evaluation","volume":"41","author":"Nishikawa","year":"2013","journal-title":"Int J Antimicrob Agents"},{"key":"2025010309474114400_dkae375-B23","author":"European Medicines Agency"},{"key":"2025010309474114400_dkae375-B24","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1038\/clpt.2014.131","article-title":"Pulmonary penetration of piperacillin and tazobactam in critically ill patients","volume":"96","author":"Felton","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"2025010309474114400_dkae375-B25","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.ijantimicag.2017.03.025","article-title":"Pharmacokinetics of piperacillin-tazobactam in plasma, peritoneal fluid and peritoneum of surgery patients, and dosing considerations based on site-specific pharmacodynamic target attainment","volume":"50","author":"Murao","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"2025010309474114400_dkae375-B26","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.jiac.2015.04.015","article-title":"Penetration of piperacillin-tazobactam into human prostate tissue and dosing considerations for prostatitis based on site-specific pharmacokinetics and pharmacodynamics","volume":"21","author":"Kobayashi","year":"2015","journal-title":"J Infect Chemother"},{"key":"2025010309474114400_dkae375-B27","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1111\/cts.12585","article-title":"Ceftazidime-avibactam population pharmacokinetic modeling and pharmacodynamic target attainment across adult indications and patient subgroups","volume":"12","author":"Li","year":"2019","journal-title":"Clin Transl Sci"},{"key":"2025010309474114400_dkae375-B28","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/jcph.1733","article-title":"Population pharmacokinetic analysis for plasma and epithelial lining fluid ceftolozane\/tazobactam concentrations in patients with ventilated nosocomial pneumonia","volume":"61","author":"Zhang","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"2025010309474114400_dkae375-B29","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/psp4.12462","article-title":"Population pharmacokinetic analysis for imipenem-relebactam in healthy volunteers and patients with bacterial infections","volume":"8","author":"Bhagunde","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2025010309474114400_dkae375-B30","doi-asserted-by":"publisher","first-page":"e0260620","DOI":"10.1128\/AAC.02606-20","article-title":"Population pharmacokinetics of meropenem and vaborbactam based on data from noninfected subjects and infected patients","volume":"65","author":"Trang","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2025010309474114400_dkae375-B31","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13054-015-0750-y","article-title":"Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?","volume":"19","author":"Udy","year":"2015","journal-title":"Crit Care"},{"key":"2025010309474114400_dkae375-B32","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1007\/s00134-023-07154-0","article-title":"Towards model-informed precision dosing of piperacillin: multicenter systematic external evaluation of pharmacokinetic models in critically ill adults with a focus on Bayesian forecasting","volume":"49","author":"Greppmair","year":"2023","journal-title":"Intensive Care Med"},{"key":"2025010309474114400_dkae375-B33","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/cpt.2104","article-title":"Model-informed drug development for antimicrobials: translational PK and PK\/PD modeling to predict an efficacious human dose for apramycin","volume":"109","author":"Sou","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"2025010309474114400_dkae375-B34","author":"European Committee on Antimicrobial Susceptibility Testing"},{"key":"2025010309474114400_dkae375-B35","author":"European Committee on Antimicrobial Susceptibility Testing"},{"key":"2025010309474114400_dkae375-B36","author":"European Committee on Antimicrobial Susceptibility Testing"},{"key":"2025010309474114400_dkae375-B37","author":"European Committee on Antimicrobial Susceptibility Testing"},{"key":"2025010309474114400_dkae375-B38","author":"European Committee on Antimicrobial Susceptibility Testing"},{"key":"2025010309474114400_dkae375-B39","doi-asserted-by":"publisher","first-page":"S84\u20135","DOI":"10.1007\/s10928-015-9432-2","article-title":"Simulation from ODE-based population PK\/PD and systems pharmacology models in R with mrgsolve","volume":"42","author":"Baron","year":"2015","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2025010309474114400_dkae375-B40","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ijantimicag.2007.12.009","article-title":"Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections","volume":"31","author":"McKinnon","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"2025010309474114400_dkae375-B41","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/phar.2842","article-title":"International consensus recommendations for the use of prolonged-infusion beta-lactam antibiotics: endorsed by the American College of Clinical Pharmacy, British Society for Antimicrobial Chemotherapy, Cystic Fibrosis Foundation, European Society of Clinical Microbiology and Infectious Diseases, Infectious Diseases Society of America, Society of Critical Care Medicine, and Society of Infectious Diseases Pharmacists","volume":"43","author":"Hong","year":"2023","journal-title":"Pharmacotherapy"},{"key":"2025010309474114400_dkae375-B42","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13054-019-2378-9","article-title":"Optimization of the treatment with beta-lactam antibiotics in critically ill patients\u2014guidelines from the French Society of Pharmacology and Therapeutics (Soci\u00e9t\u00e9 Fran\u00e7aise de Pharmacologie et Th\u00e9rapeutique\u2014SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019Anesth\u00e9sie et R\u00e9animation\u2014SFAR)","volume":"23","author":"Guilhaumou","year":"2019","journal-title":"Crit Care"},{"key":"2025010309474114400_dkae375-B43","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper","volume":"46","author":"Abdul-Aziz","year":"2020","journal-title":"Intensive Care Med"},{"key":"2025010309474114400_dkae375-B44","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12879-020-4781-x","article-title":"The effect of therapeutic drug monitoring of beta-lactam and fluoroquinolones on clinical outcome in critically ill patients: the DOLPHIN trial protocol of a multi-centre randomised controlled trial","volume":"20","author":"Abdulla","year":"2020","journal-title":"BMC Infect Dis"},{"key":"2025010309474114400_dkae375-B45","doi-asserted-by":"publisher","first-page":"107032","DOI":"10.1016\/j.ijantimicag.2023.107032","article-title":"Therapeutic drug monitoring of vancomycin and meropenem: illustration of the impact of inaccurate information in dose administration time","volume":"63","author":"Swartling","year":"2024","journal-title":"Int J Antimicrob Agents"},{"key":"2025010309474114400_dkae375-B46","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1002\/jcph.1510","article-title":"Monte Carlo simulation methodologies for \u03b2-lactam\/\u03b2-lactamase inhibitor combinations: effect on probability of target attainment assessments","volume":"60","author":"Kidd","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"2025010309474114400_dkae375-B47","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/S0924-8579(02)00024-9","article-title":"Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations","volume":"19","author":"Liu","year":"2002","journal-title":"Int J Antimicrob Agents"},{"key":"2025010309474114400_dkae375-B48","doi-asserted-by":"publisher","first-page":"11663","DOI":"10.1073\/pnas.1205073109","article-title":"Avibactam is a covalent, reversible, non-\u03b2-lactam \u03b2-lactamase inhibitor","volume":"109","author":"Ehmann","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025010309474114400_dkae375-B49","doi-asserted-by":"publisher","first-page":"e00564-19","DOI":"10.1128\/AAC.00564-19","article-title":"Molecular basis of class a \u03b2-lactamase inhibition by relebactam","volume":"63","author":"Tooke","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2025010309474114400_dkae375-B50","doi-asserted-by":"publisher","first-page":"e00398-20","DOI":"10.1128\/AAC.00398-20","article-title":"Structural basis and binding kinetics of vaborbactam in class a \u03b2-lactamase inhibition","volume":"64","author":"Pemberton","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"2025010309474114400_dkae375-B51","doi-asserted-by":"publisher","first-page":"4S10","DOI":"10.1016\/S1198-743X(14)65031-X","article-title":"\u03b2-Lactamases: quantity and resistance","volume":"3","author":"Livermore","year":"1997","journal-title":"Clin Microbiol Infect"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/1\/79\/59965385\/dkae375.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/1\/79\/59965385\/dkae375.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T09:48:01Z","timestamp":1735897681000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/1\/79\/7831305"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,22]]},"references-count":51,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,10,22]]},"published-print":{"date-parts":[[2025,1,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae375","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,10,22]]}}}